Protocol Ledger

NCT04146051 · Phase II · ACTIVE NOT RECRUITING

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Interventional Phase II clinical trial protocol NCT04146051 sponsored by Cartesian Therapeutics in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-12-04 Enrollment: 30 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04146051
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04146051
Protocol FieldVerified Registry Value
NCT IdentifierNCT04146051
Consolidated Lead SponsorCartesian Therapeutics
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment30 participants (ESTIMATED)
Registered Start Date2019-12-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI